Nasdaq:US$15.69 (+0.28) | HKEX:HK$25.40 (+0.50) | AIM:£2.21 (-0.02)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors